BLCO Stock — Bausch + Lomb Corp

Bausch + Lomb Corp (BLCO)

Updated October 16, 2026.

BLCO is a Stock. Total return is -8.4% over the past 4.4 years, 104.3 points behind SPY at 95.9%.

Bausch + Lomb Corporation operates as an eye health company with three business segments: Vision Care (contact lenses and eye care products), Pharmaceuticals (treatments for glaucoma, dry eye, and retinal diseases), and Surgical (medical devices and equipment for eye procedures). The company does not currently have an established distribution schedule. Bausch + Lomb serves patients globally through direct sales and independent distributors and operates as a subsidiary of Bausch Health Companies Inc.

BLCO performance versus SPY

Price and return data through 2026-10-16.

Total return is -8.4% over the past 4.4 years, 104.3 points behind SPY at 95.9%. Over the past year its total return — price change plus distributions reinvested — is 11.0%. Its deepest 1-year drawdown was 20.1%.

BLCO key facts

Asset type

Stock

Asset class

Equity

Inception date

05/05/2022

Distribution frequency

None

Last close

$16.49 (as of 2026-10-16)

Market cap

$5,889,654,907

Average volume

419845.0

Beta

0.561

Payout ratio

0.0%

Forward P/E

11.3636

EPS

$-0.49

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BLCO risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 20.1%.

Who may consider BLCO — and who may not

It is a weaker fit for investors who need monthly cash flow (BLCO does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BLCO

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions